

Telephone Nos. :
Regd. Office : (044) 28522745
Factory : (044) 26234300
(044) 26258511



Telefax : 044 - 26257121
Web : www.wheelsindia.com

WHEELS INDIA LIMITED

Corporate Identity Number : L35921TN1960PLC004175

Registered Office :
21, Patullos Road, Chennai - 600 002.

Factory :
Padi, Chennai - 600 050.

June 20, 2025

To
National Stock Exchange of India Limited
The Manager, Listing Department,
"Exchange Plaza", C-1, Block G,
Bandra-Kurla Complex, Bandra (E),
Mumbai – 400 051

To
BSE Limited
The Corporate Relationship Department,
1st Floor New Trading Wing, Rotunda Building,
Phiroze Jeejeebhoy Towers, Dalal Street,
Mumbai – 400 001

Symbol: WHEELS

Scrip Code: 590073

Dear Sir / Madam,

Subject: Newspaper Advertisement – Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR')

We enclose herewith copies of the newspaper advertisements published in Financial Express (English - All India edition) and Makkal Kural (Tamil - Chennai edition) on June 20, 2025 regarding proposed transfer of equity shares to the Investor Education and Protection Fund Authority ('IEPF') in accordance with relevant rules of the IEPF Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 and amendments thereof.

The copy of publications is also being made available on the Company's website at www.wheelsindia.com.

Kindly take it into your record and oblige us to disseminate the same on your website.

Thanking you.

Yours faithfully,

For **Wheels India Limited**

K V Lakshmi
Company Secretary & Compliance Officer

Enclosure: a/a

PLEASE ADDRESS ALL COMMUNICATIONS TO THE FACTORY

THIS IS A PUBLIC ANNOUNCEMENT FOR INFORMATION PURPOSES ONLY AND IS NOT A PROSPECTUS ANNOUNCEMENT AND DOES NOT CONSTITUTE AN INVITATION OR OFFER TO ACQUIRE, PURCHASE OR SUBSCRIBE TO SECURITIES. NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY OUTSIDE INDIA.

PUBLIC ANNOUNCEMENT



Aptus Pharma Ltd.
Connecting...Life

APTUS PHARMA LIMITED
CIN: U24230GJ2010PLC061957

Our Company was originally incorporated as "Aptus Pharma Private Limited" as a private limited company under the Companies Act, 1956, with the Registrar of Companies ("ROC"), Gujarat, pursuant to a Certificate of Incorporation dated August 12, 2010. Subsequently, our Company was converted into a public limited company pursuant to a resolution passed by our Shareholders at an extraordinary general meeting held on November 30, 2024 and consequently the name of our Company was changed to "Aptus Pharma Limited" and a fresh certificate of incorporation dated November 12, 2024 was issued by the Registrar of Companies, Central Processing Centre. For further details please refer to charter titled "History and Certain Corporate Matters" beginning on Page 161 of this Draft Red Herring Prospectus.

Registered Office: Ashutosh Buldoon, Opp. Sank-2, Nr. HariKrupa Logistic Park, Astali, Ahmedabad, Daskroi, Gujarat, India, 382427.
Corporate Office: SHREE BUILDING 1st Floor Opp Satyashai Heart Hospital, Narayan Nagar Kalawad Road, Rajkot Sar Unn Area Rajkot, Gujarat, 360005
Telephone: +91 79004 27827. **Email:** info@aptuspharma.com. **Website:** www.aptuspharma.com.

OUR PROMOTERS: TEJASH HANESHWANDRA HATTA, CHATRABHAI VALLABHJI BUTANI, KAPILASHI HANSMUKHJI CHANDARANI, GHANSHYAM VINUBHAI RANUSURI, MILLY CHETAN LALSETA, RIDDHISH NARWALAK TAINA, GAURANG RAMESHWANDRA THAKKER, KRIPALIBEN MAYANK THAKKER AND KUNJAL PIVYSHWALI UNADAK

"THIS ISSUE IS BEING MADE IN ACCORDANCE WITH CHAPTER IX OF THE SEBI ICDR REGULATIONS (IPO OF SMALL AND MEDIUM ENTERPRISES) AND THE EQUITY SHARES ARE PROPOSED TO BE LISTED ON SME PLATFORM OF BSE LIMITED."

THE ISSUE

INITIAL PUBLIC ISSUE OF UPTO 20,00,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH ("EQUITY SHARES") OF APTUS PHARMA LIMITED ("THE COMPANY" OR "APTUS" OR "ISSUER") FOR CASH AT A PRICE OF ₹ 1/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 1/- PER EQUITY SHARE ("THE ISSUE PRICE") AGGREGATING TO ₹ 1/- ("THE ISSUE"), OF WHICH ₹ 1/- PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH FOR CASH AT A PRICE OF ₹ 1/- PER EQUITY SHARE INCLUDING A SHARE PREMIUM OF ₹ 1/- PER EQUITY SHARE AGGREGATING TO ₹ 1/- WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("THE MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. NET ISSUE OF ₹ 1/- PER EQUITY SHARE OF FACE VALUE OF ₹ 10/- EACH AT A PRICE OF ₹ 1/- PER EQUITY SHARE AGGREGATING TO ₹ 1/- LACS IS HEREIN REFERRED TO AS THE "NET ISSUE". THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 10% AND 1% RESPECTIVELY OF THE POST ISSUE PAID UP EQUITY SHARE OF OUR COMPANY. THE PRICE BAND AND THE MINIMUM BIDDING WILL BE ₹ 10/- TO ₹ 15/- AND ₹ 10/- TO ₹ 15/- RESPECTIVELY. THE ISSUE WILL BE OPENED FOR SUBSCRIPTION ON JUNE 23, 2025 (NATIONAL DAILY NEWSPAPER) AND 1 (A WIDELY CIRCULATED HINDI NATIONAL DAILY NEWSPAPER) AND 1 (A WIDELY CIRCULATED GUJARATI NATIONAL DAILY NEWSPAPER) WHERE OUR REGISTERED OFFICE IS LOCATED, AT LEAST TWO WORKING DAYS PRIOR TO THE BID/ISSUE OPENING DATE AND SHALL BE MADE AVAILABLE TO THE SME PLATFORM OF BSE LIMITED ("BSE SME") FOR THE PURPOSE OF UPLOADING ON THEIR WEBSITE.

In case of any revision in the Price Band, the Bid/Issue Period shall be extended for at least three additional Working Days after each revision of the Price Band, subject to the total Bid/Issue Period not exceeding 10 Working Days. In cases of force majeure, banking strike or similar circumstances, our Company, for reasons to be recorded in writing, extend the Bid/Issue Period for a minimum of three Working Days, subject to the Bid/Issue Period not exceeding 10 Working Days. Any revision in the Price Band, and the revised Bid/Issue Period, if applicable, shall be widely disseminated by notification to the Stock Exchanges by issuing a press release and also by indicating the change on the website of the BRLM and at the terminals of the Members of the Syndicate and by information to designated Intermediaries and Sponsor Bank as applicable. The issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 23 of the SEBI (ICDR) Regulations, as amended, wherein ₹ 1 (not more than 50% of the Net Issue) shall be allocated to a proportionate basis to Qualified Institutional Buyers ("QIBs"), the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares shall be added to the Net QIB Portion shall be available for allocation on a proportionate basis to Non-Institutional Bidders, out of which (a) one third of such portion was reserved for applicants with application size of more than 2 lots and up to such lots equivalent to not more than 10,00,000 and (b) two-third of such portion was reserved for applicants with application size of more than 10,00,000 provided that the portion reserved in either of such sub-categories could have been allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. Further, Equity Shares capital will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Bids using the UPI Mechanism. If applicable, in which the corresponding Bid Amounts will be blocked by the SCRS or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the issue through ASBA process. For details, see "Issue Procedure" beginning on page 275 of this Draft Red Herring Prospectus.

This public announcement is being made in compliance with the Regulation 247 of SEBI (ICDR) Regulations, 2015 and SEBI (ICDR) (Amendment) Regulations, 2025 vide notification dated March 03, 2025, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies, for fulfilling all additional eligibility criteria, the DRHP filed with the SME Platform of BSE Limited ("BSE SME") shall be made available to the public for comments, if any, for a period of at least 21 days, from the date of such filing by hosting it on the website of the BSE at <https://www.bseindia.com/india/20250303/2025030325335.pdf>, and the website of the Company at www.aptuspharma.com, and at the website of BRLM i.e. INTERACTIVE FINANCIAL SERVICES LIMITED at www.ifscs.in. Our Company hereby invites the members of the public to give their comments on the DRHP filed with the SME Platform of BSE Limited ("BSE SME") with respect to disclosures made in the DRHP. The members of the public are requested to send a copy of their comments to Stock Exchange, to Company Secretary and Compliance Officer of our Company and/or the BRLM at their respective addresses mentioned below. All comments must be received by BSE and/or our Company and/or Company Secretary and Compliance Officer of our Company and/or the BRLM in relation to the offer on or before 5 p.m. on the 21st day from the aforesaid date of filing the DRHP with BSE SME.

Investments in Equity and Equity-related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their entire investment. Investors are advised to read the risk factors carefully before taking an investment decision in this issue. For taking an investment decision, investors must rely on their own examination of the Company and the issue including the risks involved. The Equity Shares issued in this issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the section "Risk Factors" beginning on page 26 of the Draft Red Herring Prospectus. Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Red Herring Prospectus as there may be material changes in the Draft Red Herring Prospectus from the Draft Red Herring Prospectus. The equity shares, when offered through the Red Herring Prospectus, are proposed to be listed on SME Platform of BSE ("BSE SME"). For details of the share capital and capital structure of our Company and the names of the signatories to the Memorandum of Association and the number of shares subscribed by them of our Company, see "Capital Structure" beginning on page 60 of the Draft Red Herring Prospectus. The ability of the members of our Company is limited. For details of the share capital, capital structure of our Company, the names of the signatories to the Memorandum of Association and the number of shares of our Company subscribed by them of our Company, please see "Capital Structure" beginning on page 72 of the Draft Red Herring Prospectus.

LEAD MANAGER OF THE ISSUE	REGISTRAR TO THE ISSUE	COMPANY SECRETARY AND COMPLIANCE OFFICER
INTERACTIVE FINANCIAL SERVICES LIMITED Address: Office No. 508, First Floor, Privara, Nehru Nagar, Ahmedabad - 380 015, Gujarat, India Tel No.: 079 4068 8019 (M) +91-9890055647 Web Site: www.ifscs.in Email: info@ifscs.in Investor Grievance e-mail: investorgrievance@ifscs.in Investor Grievance Email: investorgrievance@ifscs.in Contact Person: Pradip Sandhu SEBI Reg. No.: INR000012556	BISPHARE SERVICES PRIVATE LIMITED Address: Office No. 562-B, 6th Floor, Pinnacle Business Park, Near to: Alcanse Centre, Mahakal Caves Road, Andheri (East), Mumbai - 400093 Email: info@bisphare.com Investor Grievance e-mail: investorgrievance@bisphareonline.com Website: www.bisphareonline.com Contact Person: Babu Raphael C SEBI Registration Number: INR000001385	NAME: Mohini Hardik Gandhi Address: Ashutosh Buldoon, Opp. Sank-2, Nr. HariKrupa Logistic Park, Astali, Ahmedabad, Daskroi, Gujarat, India, 382427 E-mail: info@aptuspharma.com Investor grievance id: compliance@aptuspharma.com Investors can contact our Company Secretary and Compliance Officer, the Lead Managers or the Registrar to the issue, in case of any pre-issue or post-issue related problems, such as non-receipt of letters of allotment, non-credit of allotted Equity Shares in the respective beneficiary account, non-receipt of refund orders and non-receipt of funds by electronic mode etc.

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed to them in the DRHP.

Place: Ahmedabad
Date: June 20, 2025

Disclaimer: APTUS PHARMA LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus on June 18, 2025. The Draft Red Herring Prospectus is available on the website of BSE SME at <https://www.bseindia.com/india/20250303/2025030325335.pdf> and is also available on the website of the BRLM at www.ifscs.in and also on the website of the Company www.aptuspharma.com. Any potential investors should note that investment in equity shares involves a high degree of risk and for details relating to the same, see section titled "Risk Factors" beginning on page 26 of the Draft Red Herring Prospectus. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. Any Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act") or any state securities laws in the United States, and unless so registered, and may not be issued or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with any applicable U.S. State Securities Laws. The Equity Shares are being issued and sold outside the United States in reliance on the exemption from registration under the Securities Act and the applicable laws of each jurisdiction where such issues and sales are made. There will be no public offering in the United States.

indianexpress.com

Look at every side
before taking a side.

Inform your opinion with
insightful perspectives.

The Indian Express.
For the Indian Intelligent.

The Indian EXPRESS
JOURNALISM OF COURAGE

paper.financialexpress.com

VEGORAMA PUNJABI ANGITHI LIMITED

CIN: U55101DL2022PLC9395857

Our Company was originally incorporated as a Private Limited Company under the name of "Vegorama Punjabi Angithi Private Limited" on March 30, 2022 under the provisions of the Companies Act, 2013 with the Registrar of Companies, Net of India. Subsequently, our Company was converted into Public Limited pursuant to resolution passed by our shareholders at Extra ordinary general meeting held on March 05, 2025 and a fresh Certificate of Incorporation pursuant to conversion into public limited dated April 09, 2025 issued by the Registrar of Companies, Central Processing Centre. For details of registered office of our Company, please refer to the section title "History and Corporate Structure" on page no. 192 of this Draft Red Herring Prospectus.

Registered Office: B-376, Third Floor, Meera Bagh, Outer Ring Road, Paschim Vihar, New Delhi-110063
Telephone: +91-11-46112637. **Website:** www.punjabiangithi.in. **E-mail:** compliance@punjabiangithi.in
Company Secretary and Compliance Officer: Ms. Karuna Sharma
OUR PROMOTER: MR. DEEPAK CHADHA

DETAILS OF THE ISSUE

INITIAL PUBLIC ISSUE OF UP TO 49,84,000 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH OF VEGORAMA PUNJABI ANGITHI LIMITED FOR CASH AT ISSUE PRICE OF ₹ 1/- PER EQUITY SHARE INCLUDING A PREMIUM OF ₹ 1/- PER EQUITY SHARE ("THE ISSUE PRICE") AGGREGATING UP TO ₹ 1/- LAKHS COMPRISING OF FRESH ISSUE OF UP TO 39,87,200 EQUITY SHARES AGGREGATING TO ₹ 1/- LAKHS ("FRESH ISSUE") AND AN OFFER FOR SALE OF UP TO 9,96,800 EQUITY SHARES BY MR. DEEPAK CHADHA ("SELLING SHAREHOLDERS") AGGREGATING TO ₹ 1/- LAKHS ("OFFER FOR SALE") ("THE ISSUE") AND UP TO 2,51,200 EQUITY SHARES AT AN ISSUE PRICE OF ₹ 1/- PER SHARE AGGREGATING TO ₹ 1/- LAKHS WILL BE RESERVED FOR SUBSCRIPTION BY MARKET MAKER ("MARKET MAKER RESERVATION PORTION"). THE ISSUE LESS THE MARKET MAKER RESERVATION PORTION I.E. ISSUE OF UP TO 47,32,800 EQUITY SHARES OF FACE VALUE OF ₹ 10/- EACH AT AN ISSUE PRICE OF ₹ 1/- PER EQUITY SHARE AGGREGATING TO ₹ 1/- LAKHS ("NET ISSUE"). THE ISSUE AND THE NET ISSUE WILL CONSTITUTE 30% AND 28.49% OF THE POST-ISSUE PAID-UP EQUITY SHARE CAPITAL OF OUR COMPANY. PLEASE REFER TO SECTION TITLED "TERMS OF THE ISSUE" BEGINNING ON PAGE NO. 281 OF THIS DRAFT RED HERRING PROSPECTUS.

The Issue is being made through the Book Building Process, in terms of Rule 19(2)(b) of the Securities Contracts (Regulation) Rules, 1957, as amended ("SCRR") read with Regulation 23 of the SEBI ICDR Regulations, as amended, wherein not more than 50% of the Net Issue shall be allocated on a proportionate basis to Qualified Institutional Buyers ("QIBs"), the "QIB Portion", provided that our Company may, in consultation with the Book Running Lead Managers, allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis in accordance with the SEBI ICDR Regulations ("Anchor Investor Portion"), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds or above the Anchor Investor Allocation Price. In the event of under-subscription, or non-allocation in the Anchor Investor Portion, the balance Equity Shares shall be added to the Net QIB Portion shall be available for allocation on a proportionate basis only to Mutual Funds, and the remainder of the Net QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received at or above the Issue Price. However, if the aggregate demand from Mutual Funds is less than 5% of the Net QIB Portion, the balance Equity Shares shall be added to the Net QIB Portion shall be available for allocation on a proportionate basis to Non-Institutional Bidders, out of which (a) one third of such portion was reserved for applicants with application size of more than 2 lots and up to such lots equivalent to not more than 10,00,000 and (b) two-third of such portion was reserved for applicants with application size of more than 10,00,000 provided that the portion reserved in either of such sub-categories could have been allocated to applicants in the other sub-category of Non-Institutional Bidders and not less than 35% of the Net Issue shall be available for allocation to individual Bidders in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Issue Price. Further, Equity Shares capital will be allocated on a proportionate basis to Eligible Employees applying under the Employee Reservation Portion, subject to valid Bids. All potential Bidders (except Anchor Investors) are required to mandatorily utilize the Application Supported by Blocked Amount ("ASBA") process providing details of their respective ASBA accounts, and UPI ID in case of Bids using the UPI Mechanism. If applicable, in which the corresponding Bid Amounts will be blocked by the SCRS or by the Sponsor Bank under the UPI Mechanism, as the case may be, to the extent of respective Bid Amounts. Anchor Investors are not permitted to participate in the issue through ASBA process. For details, see "Issue Procedure" beginning on page no. 298 of this Draft Red Herring Prospectus. Provided further that for the purpose of public issue by the section title to be listed on SME exchange made in accordance with Chapter IX of these regulations, the words "Retail Individual Investors" shall be read as words "individual investors" who applies for minimum application size. A copy will be filed with the Registrar of Companies as required under Section 26 of the Companies Act, 2013.

THE FACE VALUE OF THE EQUITY SHARES IS ₹ 10/- EACH AND THE ISSUE PRICE IS ₹ 1/- TIMES OF THE FACE VALUE

This public announcement is being made in compliance with and in accordance with SEBI press release no. PR No. 36/2024 dated December 18, 2024 (2024 SEBI Band meeting on "Retail of SME framework under SEBI (ICDR) Regulations, 2015, and applicability of corporate governance provisions under SEBI (LODR) Regulations, 2015 on SME companies) to inform the public that our Company is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake initial public offering of its Equity Shares pursuant to the issue and has filed the Draft Red Herring Prospectus dated June 18, 2025 which has been filed with the SME Platform of BSE Limited ("BSE SME") on BSE SME. All potential investors are not permitted to participate in the issue through ASBA process. For further details please refer the section titled "Issue Procedure" beginning on page no. 298 of this Draft Red Herring Prospectus. Provided further that for the purpose of public issue by the section title to be listed on SME exchange made in accordance with Chapter IX of these regulations, the words "Retail Individual Investors" shall be read as words "individual investors" who applies for minimum application size. A copy will be filed with the Registrar of Companies as required under Section 26 of the Companies Act, 2013.

Investment in equity and equity related securities involve a degree of risk and investors should not invest any funds in this issue unless they can afford to take the risk of losing their investment. Investors are advised to read the risk factors carefully before taking an investment decision in this issue. For taking an investment decision, investors must rely on their own examination of the issue and the issue including the risks involved. The Equity Shares issued in this issue have not been recommended or approved by the Securities and Exchange Board of India ("SEBI"), nor does SEBI guarantee the accuracy or adequacy of the Draft Red Herring Prospectus. Specific attention of the investors is invited to the statement of "Risk Factors" given on page 30 of the Draft Red Herring Prospectus. Any decision to invest in the equity shares described in the Draft Red Herring Prospectus may only be taken after a Red Herring Prospectus has been filed with the ROC and must be made solely on the basis of such Prospectus as there may be material changes in the Draft Red Herring Prospectus from the Draft Red Herring Prospectus.

The Equity Shares, when offered, through the Red Herring Prospectus, and proposed to be listed on the SME Platform of BSE Limited ("BSE SME" or "BSE"), for details of the main objects of our Company as contained in a Memorandum of Association, see "History and Corporate Structure" on page 192 of the Draft Red Herring Prospectus.

The liability of the members of our Company is limited. For details of the share capital, capital structure of our Company, the names of the signatories to the Memorandum of Association and the number of shares of our Company subscribed by them of our Company, please see "Capital Structure" beginning on page 72 of the Draft Red Herring Prospectus.

CORPORATE PARTNERS CAPITAL LIMITED	BISPHARE SERVICES PVT. LTD.
Address: Office No. 562-B, 6th Floor, Pinnacle Business Park, Near to: Alcanse Centre, Mahakal Caves Road, Andheri (East), Mumbai - 400093 Telephone: 011 41416600 Email: info@corporatemarkers.in Website: www.corporatemarkers.in Investor grievance email: compliance@corporatemarkers.in Investor grievance email: investor@bisphareonline.com Contact Person: Mr. Rohit Pareek SEBI Registration Number: INR000013098 CIN: U55101DL1994PLC036890	Office: 508, First Floor, Privara Business Park, Near to: Alcanse Centre, Mahakal Caves Road, Andheri (East), Mumbai - 400093 Telephone: 022-26324200 Email: info@bisphareonline.com Investor grievance email: investor@bisphareonline.com Website: www.bisphareonline.com Contact Person: Mr. Babu Raphael C SEBI Registration Number: INR000001385 CIN: U99999MH1994PLC076534

All capitalized terms used herein and not specifically defined shall have the same meaning as ascribed in the Draft red herring Prospectus

For Vegorama Punjabi Angithi Limited On behalf of the Board of Directors		
Date - June 19, 2025 Place - New Delhi	 Karuna Sharma Company Secretary and Compliance Officer	Sd/-
Vegorama Punjabi Angithi Limited is proposing, subject to receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has filed the Draft Red Herring Prospectus with BSE on June 18, 2025. The Draft Red Herring Prospectus shall be available on the website of the BSE at www.bseindia.com and is available on website of the Company i.e., www.punjabiangithi.in, website of the Lead Manager to the issue, Corporate Marketers Capital Limited at www.corporatemarketers.in. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, please see the section entitled "Risk Factors" on page 30 of the Draft Red Herring Prospectus and the details set out in the Prospectus, when filed. Potential investors should not rely on the Draft Red Herring Prospectus for making any investment decision. This announcement has been prepared for publication in India and may not be released in the United States. This announcement does not constitute an offer of securities for sale in any jurisdiction, including the United States, and any securities described in this announcement may not be offered or sold in the United States or any other country except pursuant to an exemption from registration. Any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company and that will contain detailed information about the Company and management, as well as financial statements. However, the securities described in this announcement are not being offered or sold in the United States.		

Wheels India Limited

CIN: U52400DL2012PLC0420024

Address: Office No. 562-B, 6th Floor, Pinnacle Business Park, Near to: Alcanse Centre, Mahakal Caves Road, Andheri (East), Mumbai - 400093

Telephone: 022-26324200

Email: info@wheelsindia.com

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

Investor grievance email: investorgrievance@wheelsindia.com

Website: www.wheelsindia.com

Contact Person: Mr. Ravi Kumar

SEBI Registration Number: INR000001385

CIN: U52400DL1994PLC0420024

FIDELITY MARKET & FINCAP PRIVATE LIMITED

CIN: U55109WB1994PTC062119

Address: Office No. 562-B, 6th Floor, Pinnacle Business Park, Near to: Alcanse Centre, Mahakal Caves Road, Andheri (East), Mumbai - 400093

Telephone: 022-26324200

Email: info@fidelitymarket.com

Investor grievance email: investorgrievance@fidelitymarket.com

Website

